Aditi Dhir, MD

home / authors / aditi-dhir-md

Articles

Aditi Dhir, MD, discusses ongoing efforts in epithelioid and synovial sarcoma.

Dr. Dhir on Ongoing Research Efforts in Epithelioid and Synovial Sarcoma

Aditi Dhir, MD
February 16th 2021

Aditi Dhir, MD, discusses ongoing efforts in epithelioid and synovial sarcoma.

Read More

Aditi Dhir, MD, of Sylvester Comprehensive Center

Dr. Dhir on Risk-Based Stratification in Epithelioid and Synovial Sarcoma

Aditi Dhir, MD
February 10th 2021

Aditi Dhir, MD, discusses risk-based stratification in patients with epithelioid and synovial sarcoma.

Read More

Aditi Dhir, MD, of Sylvester Comprehensive Cancer Center

Dr. Dhir on Diagnostic Challenges in Sarcoma

Aditi Dhir, MD
February 5th 2021

Aditi Dhir, MD, discusses the challenges of diagnosing patients with sarcoma.

Read More

Aditi Dhir, MD, of Sylvester Comprehensive Center

Dr. Dhir on Modifying Treatment for Adults Versus Pediatric Patients With Epithelioid Sarcoma

Aditi Dhir, MD
January 6th 2021

Aditi Dhir, MD, discusses modifying treatment for adults versus pediatric patients with epithelioid sarcoma.

Read More

Latest Updated Articles

Real-world comparison of the efficacy and safety of atezolizumab versus durvalumab in extensive-stage small cell lung cancer
Published: December 17th 2024 | Updated: January 16th 2025
Real-world comparison of the efficacy and safety of atezolizumab versus durvalumab in extensive-stage small cell lung cancer
Ropeginterferon Alfa-2b in Essential Thrombocytopenia | Image Credit: © Tatiana Shepeleva - stock.adobe.com
Published: January 6th 2025 | Updated: January 8th 2025
Second-Line Ropeginterferon Alfa-2b Boosts Responses in Essential Thrombocythemia
OncLive co-hosts Kristie L. Kahl and Andrew Svonavec highlight abstracts for medical oncologists to look out for at the upcoming ASH Annual Meeting in San Diego, with some additional tidbits to round out the main event.
Published: December 3rd 2024 | Updated: December 6th 2024
ASH 2024 Preview for Medical Oncologists: The Show and After Show
Phase 1/2 ALKOVE-1 study of NVL-655 in ALK-positive (ALK+) solid tumors
Published: October 30th 2024 | Updated: November 7th 2024
Phase 1/2 ALKOVE-1 Study of NVL-655 in ALK-positive (ALK+) Solid Tumors
Updated Efficacy and Safety From the Phase 2 PHAROS Study of Encorafenib Plus Binimetinib in Patients With BRAF V600E-Mutant Metastatic NSCLC (mNSCLC)
Published: October 18th 2024 | Updated: October 21st 2024
Updated Efficacy and Safety From the Phase 2 PHAROS Study of Encorafenib Plus Binimetinib in Patients With BRAF V600E-Mutant Metastatic NSCLC (mNSCLC)
Daratumumab + Bortezomib/Lenalidomide/Dexamethasone in Patients With Transplant-ineligible or Transplant-deferred Newly Diagnosed Multiple Myeloma: Results of the Phase 3 CEPHEUS Study
Published: October 14th 2024 | Updated: October 16th 2024
Daratumumab + Bortezomib/Lenalidomide/Dexamethasone in Patients With Transplant-ineligible or Transplant-deferred Newly Diagnosed Multiple Myeloma: Results of the Phase 3 CEPHEUS Study